Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Equity Income (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Equity Income for 3 consecutive years, with -$21.0 million as the latest value for Q4 2025.

  • Quarterly Equity Income fell 147.4% to -$21.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$72.6 million through Dec 2025, down 215.85% year-over-year, with the annual reading at -$72.6 million for FY2025, 132.84% down from the prior year.
  • Equity Income hit -$21.0 million in Q4 2025 for BridgeBio Pharma, down from -$15.8 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of -$6.6 million in Q3 2024 to a low of -$21.0 million in Q4 2025.